Literature DB >> 29071405

Requirements for Using iPSC-Based Cell Models for Assay Development in Drug Discovery.

Klaus Christensen1, Filip Roudnicky1, Christoph Patsch1, Mark Burcin2.   

Abstract

A prevalent challenge in drug discovery is the translation of findings from preclinical research into clinical success. Currently, more physiological in vitro systems are being developed to overcome some of these challenges. In particular, induced pluripotent stem cells (iPSCs) have provided the opportunity to generate human cell types that can be utilized for developing more disease-relevant cellular assay models. As the use of these complex models is lengthy and fairly complicated, we lay out our experiences of the cultivation, differentiation, and quality control requirements to successfully utilize pluripotent stem cells in drug discovery.

Entities:  

Keywords:  Assay development; Disease models; Drug discovery; Genomic integrity stability; Human pluripotent stem cells; Induced pluripotent stem cells; Quality control requirements

Mesh:

Year:  2018        PMID: 29071405     DOI: 10.1007/10_2017_23

Source DB:  PubMed          Journal:  Adv Biochem Eng Biotechnol        ISSN: 0724-6145            Impact factor:   2.635


  1 in total

1.  How Qualification of 3D Disease Models Cuts the Gordian Knot in Preclinical Drug Development.

Authors:  Monika Schäfer-Korting; Christian Zoschke
Journal:  Handb Exp Pharmacol       Date:  2021
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.